- ~39% General Response Charge (ORR): 1 CR and 6 PRs (2 awaiting affirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC sufferers
- ~94% Illness Management Charge (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1
- ~78% of Sufferers with Tumor Shrinkage: 14 sufferers noticed tumor shrinkage
- ~81% ctDNA Molecular Response Charge (MRR): 13 of 16 sufferers with > 50% ctDNA discount
- AE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day growth dose
- IDE397 growth dose of 30 mg once-a-day achieved goal drug protection and plasma SAM pharmacodynamic discount related to preclinical tumor regressions
- ~48k U.S. annual incidence of MTAP-deletion urothelial most cancers and NSCLC, with excessive unmet want and no FDA-approved therapies for MTAP-deletion stable tumors
- Investor webcast scheduled for right this moment, Monday, July 8, 2024, at 8:00 am ET
SOUTH SAN FRANCISCO, Calif., July 8, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision drugs oncology firm dedicated to the invention and improvement of focused therapeutics, right this moment introduced constructive scientific information for the IDE397 Section 2 monotherapy growth dose in methylthioadenosine phosphorylase (MTAP)-deletion urothelial and non-small cell lung most cancers (NSCLC) sufferers. IDE397 is a potent and selective potential first-in-class methionine adenosyltransferase 2 alpha (MAT2A) inhibitor in Section 2 scientific trials for the remedy of MTAP-deletion stable tumors.
“We’re extremely inspired by the preliminary scientific efficacy and favorable security profile noticed with IDE397 on the 30mg once-a-day growth dose, together with a number of partial responses and one full response by RECIST 1.1 in MTAP-deletion urothelial and lung most cancers sufferers. As well as, at this growth dose we noticed a good opposed occasion profile with no drug-related critical opposed occasions and mid-single digit % grade 3 or greater drug-related opposed occasions, which we imagine has the potential to allow longer length dosing in addition to mixtures,” mentioned Dr. Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.
“IDE397 is a possible first-in-class MAT2A inhibitor, that’s being superior as a monotherapy agent in precedence MTAP-deletion stable tumor varieties and in excessive conviction rational mixtures, together with with Amgen’s investigational MTA-cooperative protein arginine methytranferase 5 inhibitor AMG 193 in NSCLC and with Gilead’s Trop-2 directed anti-body conjugate Trodelvy in urothelial most cancers. The IDE397 scientific information replace demonstrates necessary scientific proof-of-concept in MTAP-deletion stable tumors to ship RECIST responses and inspiring preliminary sturdiness, with a handy 30mg once-a-day pill and favorable opposed occasion profile,” mentioned Yujiro S. Hata, Chief Govt Officer and Founder, IDEAYA Biosciences.
There are at the moment no FDA-approved therapies for sufferers with MTAP-deletion stable tumors, highlighting the unmet medical want. The precedence MTAP-deletion stable tumor varieties for the IDE397 Section 2 monotherapy program are urothelial most cancers and NSCLC. MTAP-deletion prevalence has been reported at over 15% in NSCLC and over 25% in urothelial most cancers, based mostly on The Most cancers Genome Atlas (TCGA) database. We estimate that the MTAP-deletion annual incidence within the U.S. in NSCLC and urothelial most cancers is roughly 48,000 sufferers, based mostly on the 2024 Surveillance, Epidemiology, and Finish Outcomes (SEER) database. As well as, there are a number of potential growth MTAP-deletion stable tumor varieties which might be additionally being thought of for monotherapy and mixture improvement, together with pancreatic, gastric, esophageal, and head and neck most cancers, amongst others. Primarily based on the TCGA database, MTAP-deletion prevalence in pancreatic most cancers has been reported at over 20%, representing a U.S. annual incidence of roughly 14,000 sufferers.
Medical Knowledge Replace – IDE397 at 30mg QD Section 2 Growth Dose in MTAP-Deletion Urothelial Most cancers and NSCLC Sufferers
The corporate noticed encouraging scientific exercise on the 30 mg growth dose in its Section 2 scientific trial evaluating its potential first-in-class MAT2A inhibitor IDE397 in closely pre-treated MTAP-deletion urothelial most cancers and NSCLC sufferers. The sufferers evaluated had a median of two (2) prior strains of remedy, starting from one (1) to seven (7) prior strains of remedy. The reported Section 2 scientific information are based mostly on eighteen (18) evaluable MTAP-deletion sufferers, together with seven (7) urothelial most cancers, 4 (4) adenocarcinoma NSCLC, and 7 (7) squamous NSCLC sufferers on the growth dose of 30 mg once-a-day of IDE397.
Reported scientific efficacy and tolerability information are preliminary and based mostly on investigator evaluate from an unlocked database as of the information evaluation cutoff date of June 21, 2024.
The scientific information replace within the eighteen (18) evaluable sufferers by RECIST 1.1 embody:
- ~39% General Response Charge (ORR). One (1) full response and 6 (6) partial responses by RECIST 1.1 analysis out of eighteen (18) evaluable sufferers. Two (2) partial responses are awaiting affirmation, together with one (1) urothelial most cancers affected person that had a 100% tumor discount within the goal lesion on the final CT-scan evaluation and one (1) adenocarcinoma NSCLC affected person. One (1) full response and two (2) partial responses have been urothelial most cancers sufferers. Amongst sufferers with lung most cancers, three (3) partial responses have been squamous NSCLC sufferers, and one (1) partial response was an adenocarcinoma NSCLC affected person. There was one (1) non-evaluable affected person who discontinued because of speedy scientific development of most cancers fatigue and drug-unrelated opposed occasions in cycle 1 of remedy
- 94% Illness Management Charge (DCR). One (1) full response, six (6) partial responses, and ten (10) secure illness by RECIST 1.1 analysis out of eighteen (18) evaluable sufferers
- 78% of sufferers with tumor shrinkage. Fourteen (14) out of eighteen (18) evaluable sufferers noticed tumor shrinkage
- Swim lane plot by CT-scan analysis and preliminary sturdiness evaluation: Eleven (11) of eighteen (18) sufferers nonetheless on remedy. 5 (5) of seven (7) RECIST 1.1 responses stay in response. Median length of remedy, median length of response, and median development free survival not but reached
- 81% ctDNA Molecular Response (MR) Charge. 13 (13) of sixteen (16) sufferers with 50% or better ctDNA discount. There have been a number of high quality management failures of affected person samples that led to unavailability for MR evaluation
- Favorable opposed occasion (AE) profile. Roughly 5.6% grade 3 or greater drug-related AEs and no drug-related critical opposed occasions (SAEs) noticed at IDE397 30mg once-a-day growth dose. No drug-related AEs resulting in discontinuations noticed. We anticipate that the favorable AE profile and dosing comfort of a 30 mg once-a-day pill has the potential to allow long-term dosing and mixture improvement
- 30mg as soon as day by day growth dose achieves goal drug protection and plasma S-adenosyl-l-methionine (SAM) pharmacodynamic discount related to preclinical tumor regressions
IDEAYA has activated over 35 scientific trial websites globally within the U.S., Canada, Europe, and Asia Pacific to allow potential speedy enrollment for the IDE397 Section 2 monotherapy growth in MTAP-deletion lung and bladder most cancers in its ongoing trial (NCT04794699). There’s additionally an Amgen-sponsored Section 1/2 trial of IDE397 and AMG 193 mixture in MTAP-Deletion NSCLC (NCT05975073) for which the businesses intend to develop a joint publication technique in 2024. As well as, IDEAYA has initiated enrollment in a Section 1 scientific trial evaluating the protection, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE397 together with Trodelvy (NCT04794699). IDEAYA can also be advancing a number of preclinical stage MTAP-deletion applications to allow wholly-owned mixtures with IDE397, together with a program focusing on a improvement candidate nomination within the second half of 2024.
IDEAYA Investor Webcast and Convention Name
IDEAYA will host an investor webcast right this moment, Monday, July 8, at 8:00 am Japanese Time (ET), to current the scientific information replace for the IDE397 Section 2 monotherapy growth dose in MTAP-deletion urothelial most cancers and NSCLC sufferers.
Presenters on the investor webcast will embody IDEAYA Biosciences administration, together with Yujiro S. Hata, Chief Govt Officer, Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, and Michael White, Ph.D., Chief Scientific Officer.
The IDE397 investor webcast presentation, in addition to an up to date company presentation, which is able to incorporate the IDE397 Section 2 scientific information replace on the 30mg growth dose in urothelial most cancers and NSCLC sufferers, can be obtainable on the corporate’s web site, at its Investor Relations portal at roughly 8:00 am ET on Monday, July 8, 2024.
About IDEAYA Biosciences
IDEAYA is a precision drugs oncology firm dedicated to the invention and improvement of focused therapeutics for affected person populations chosen utilizing molecular diagnostics. IDEAYA’s strategy integrates capabilities in figuring out and validating translational biomarkers with drug discovery to pick out affected person populations more than likely to learn from its focused therapies. IDEAYA is making use of its analysis and drug discovery capabilities to artificial lethality – which represents an rising class of precision drugs targets.
Ahead-Wanting Statements
This press launch accommodates forward-looking statements, together with, however not restricted to, statements associated to (i) expectations concerning the scientific exercise profile and potential benefits of IDEAYA’s scientific applications, (ii) the timing for the event of a joint Amgen/IDEAYA publication technique for the Section 1/2 IDE397 and AMG 193 mixture, (iii) the timing of preclinical stage MTAP-deletion applications together with IDE397 and (iv) nomination of an IDE397 mixture improvement candidate within the second half of 2024. Such forward-looking statements contain substantial dangers and uncertainties that would trigger precise occasions and outcomes to vary from these expressed in these forward-looking statements, together with these associated to IDEAYA’s preclinical and scientific improvement applications. Such dangers and uncertainties embody, amongst others, the uncertainties inherent within the drug improvement course of, together with IDEAYA’s applications’ early stage of improvement, the method of designing and conducting preclinical and scientific trials, critical opposed occasions, undesirable unwanted effects or surprising traits of drug improvement applications, the regulatory approval processes, the timing of regulatory filings, the challenges related to manufacturing drug merchandise, IDEAYA’s means to efficiently set up, shield and defend its mental property, the sufficiency of present money to fund operations, and different issues that would have an effect on the corporate’s enterprise, monetary situation, outcomes of operations and prospects. IDEAYA undertakes no obligation to replace or revise any forward-looking statements. For an extra description of the dangers and uncertainties that would trigger precise occasions and outcomes to vary from these expressed in these forward-looking statements, in addition to dangers regarding the enterprise of IDEAYA on the whole, see IDEAYA’s Annual Report on Kind 10-Okay filed on February 20, 2024, Quarterly Report on Kind 10-Q filed on Could 7, 2024 and any extra present and periodic studies filed with the U.S. Securities and Trade Fee.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
[email protected]
SOURCE IDEAYA Biosciences, Inc.
